Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Trastuzumab emtansine (Synonyms: Trastuzumab emtansine, T-DM1)

Catalog No. T36647 Copy Product Info
Purity: 98%
🥰Excellent
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody–drug conjugate that combines the HER2-targeted antitumor specificity of trastuzumab with the potent cytotoxic activity of the microtubule inhibitor DM1, Trastuzumab emtansine enables selective intracellular delivery of the cytotoxic payload to HER2-expressing cells and supporting translational and mechanistic research in advanced breast cancer models.

Trastuzumab emtansine

Copy Product Info
🥰Excellent
Catalog No. T36647
Synonyms Trastuzumab emtansine, T-DM1

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody–drug conjugate that combines the HER2-targeted antitumor specificity of trastuzumab with the potent cytotoxic activity of the microtubule inhibitor DM1, Trastuzumab emtansine enables selective intracellular delivery of the cytotoxic payload to HER2-expressing cells and supporting translational and mechanistic research in advanced breast cancer models.

Trastuzumab emtansine
Cas No. 1018448-65-1
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$597-In Stock
5 mg$1,320-In Stock
10 mg$2,150-In Stock
25 mg$3,190-In Stock
50 mg$4,280-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98%
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody–drug conjugate that combines the HER2-targeted antitumor specificity of trastuzumab with the potent cytotoxic activity of the microtubule inhibitor DM1, Trastuzumab emtansine enables selective intracellular delivery of the cytotoxic payload to HER2-expressing cells and supporting translational and mechanistic research in advanced breast cancer models.
In vitro
Trastuzumab emtansine (2 μg/mL; 3 d) markedly inhibits the proliferation of epithelial ovarian cancer (EOC) cells[2].
In vivo
Method: Trastuzumab emtansine was administered intravenously at 15 mg/kg three to five times weekly for 3 weeks in CB-17/SCID mice injected with OVA10 cells.
Result: Trastuzumab emtansine produced significant antitumor effects in tumor-bearing mice[2].
SynonymsTrastuzumab emtansine, T-DM1
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Antigen Details
Uniprot ID
TargetHER2
Chemical Properties
FormulaN/A
Cas No.1018448-65-1
Smiles[Trastuzumab emtansine]
Antibody Information
IsotypeIgG1
Storage & Solubility Information
Storagekeep away from moisture,keep away from direct sunlight,store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 160 mg/mL, Sonication is recommended.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Trastuzumab emtansine | purchase Trastuzumab emtansine | Trastuzumab emtansine cost | order Trastuzumab emtansine | Trastuzumab emtansine chemical structure | Trastuzumab emtansine in vivo | Trastuzumab emtansine in vitro | Trastuzumab emtansine formula